Skip to main content
Top
Published in: BMC Complementary Medicine and Therapies 1/2012

Open Access 01-12-2012 | Research article

Astragalus saponins downregulate vascular endothelial growth factor under cobalt chloride-stimulated hypoxia in colon cancer cells

Authors: Pui-Ching Law, Kathy K Auyeung, Lok-Yi Chan, Joshua K Ko

Published in: BMC Complementary Medicine and Therapies | Issue 1/2012

Login to get access

Abstract

Background

Our ongoing research has revealed that total saponins extracted from the medicinal herb Radix Astragali (AST) exhibits significant growth-inhibitory and proapoptotic effects in human cancer cells. In the present study, the potential of AST in controlling angiogenesis was further investigated with elaboration of the underlying molecular mechanism in human colon cancer cell and tumor xenograft.

Results

AST decreased the protein level of VEGF and bFGF in HCT 116 colon cancer cells in a time- and dose-dependent manner. Among the Akt/mTOR signal transduction molecules being examined, AST caused PTEN upregulation, reduction in Akt phosphorylation and subsequent activation of mTOR. AST also suppressed the induction of HIF-1α and VEGF under CoCl2-mimicked hypoxia. These effects were intensified by combined treatment of AST with the mTOR inhibitor rapamycin. Despite this, our data also indicate that AST could attenuate cobalt chloride-evoked COX-2 activation, while such effect on COX-2 and its downstream target VEGF was intensified when indomethacin was concurrently treated. The anti-carcinogenic action of AST was further illustrated in HCT 116 xenografted athymic nude mice. AST significantly suppressed tumor growth and reduced serum VEGF level in vivo. In the tumor tissues excised from AST-treated animals, protein level of p-Akt, p-mTOR, VEGF, VEGFR1 and VEGFR2 was down-regulated. Immunohistochemistry has also revealed that AST effectively reduced the level of COX-2 in tumor sections when compared with that in untreated control.

Conclusion

Taken together, these findings suggest that AST exerts anti-carcinogenic activity in colon cancer cells through modulation of mTOR signaling and downregulation of COX-2, which together reduce VEGF level in tumor cells that could potentially suppress angiogenesis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ho JW, Leung YK, Chan CP: Herbal medicine in the treatment of cancer. Curr Med Chem Anticancer Agents. 2002, 2: 209-214. 10.2174/1568011023354164.CrossRefPubMed Ho JW, Leung YK, Chan CP: Herbal medicine in the treatment of cancer. Curr Med Chem Anticancer Agents. 2002, 2: 209-214. 10.2174/1568011023354164.CrossRefPubMed
2.
go back to reference Velmurugan B, Singh RP, Kaul N, Agarwal R, Agarwal C: Dietary feeding of grape seed extract prevents intestinal tumorigenesis in APCmin/+ mice. Neoplasia. 2010, 12: 95-102.CrossRefPubMedPubMedCentral Velmurugan B, Singh RP, Kaul N, Agarwal R, Agarwal C: Dietary feeding of grape seed extract prevents intestinal tumorigenesis in APCmin/+ mice. Neoplasia. 2010, 12: 95-102.CrossRefPubMedPubMedCentral
3.
go back to reference Paul S, DeCastro AJ, Lee HJ, Smolarek AK, So JY, Simi B, Wang CX, Zhou R, Rimando AM, Suh N: Dietary intake of pterostilbene, a constituent of blueberries, inhibits the {beta}-catenin/p65 downstream signaling pathway and colon carcinogenesis in rats. Carcinogenesis. 2010, 31: 1272-1278. 10.1093/carcin/bgq004.CrossRefPubMedPubMedCentral Paul S, DeCastro AJ, Lee HJ, Smolarek AK, So JY, Simi B, Wang CX, Zhou R, Rimando AM, Suh N: Dietary intake of pterostilbene, a constituent of blueberries, inhibits the {beta}-catenin/p65 downstream signaling pathway and colon carcinogenesis in rats. Carcinogenesis. 2010, 31: 1272-1278. 10.1093/carcin/bgq004.CrossRefPubMedPubMedCentral
4.
go back to reference Auyeung KK, Cho CH, Ko JK: A novel anticancer effect of Astragalus saponins: transcriptional activation of NSAID-activated gene. Int J Cancer. 2009, 125: 1082-1091. 10.1002/ijc.24397.CrossRefPubMed Auyeung KK, Cho CH, Ko JK: A novel anticancer effect of Astragalus saponins: transcriptional activation of NSAID-activated gene. Int J Cancer. 2009, 125: 1082-1091. 10.1002/ijc.24397.CrossRefPubMed
5.
go back to reference Tin MM, Cho CH, Chan K, James AE, Ko JK: Astragalus saponins induce growth inhibition and apoptosis in human colon cancer cells and tumor xenograft. Carcinogenesis. 2007, 28: 1347-1355. 10.1093/carcin/bgl238.CrossRefPubMed Tin MM, Cho CH, Chan K, James AE, Ko JK: Astragalus saponins induce growth inhibition and apoptosis in human colon cancer cells and tumor xenograft. Carcinogenesis. 2007, 28: 1347-1355. 10.1093/carcin/bgl238.CrossRefPubMed
6.
go back to reference Auyeung KK, Woo PK, Law PC, Ko JK: Astragalus saponins modulate cell invasiveness and angiogenesis in human gastric adenocarcinoma cells. J Ethnopharmacol. 2012, 141 (2): 635-641. 10.1016/j.jep.2011.08.010.CrossRefPubMed Auyeung KK, Woo PK, Law PC, Ko JK: Astragalus saponins modulate cell invasiveness and angiogenesis in human gastric adenocarcinoma cells. J Ethnopharmacol. 2012, 141 (2): 635-641. 10.1016/j.jep.2011.08.010.CrossRefPubMed
7.
go back to reference Emile EV, Patricia AD: Tumor angiogenesis and microcirculation. 2001, Marcel Dekker Inc, New York, 1-8. Emile EV, Patricia AD: Tumor angiogenesis and microcirculation. 2001, Marcel Dekker Inc, New York, 1-8.
8.
go back to reference Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature. 1993, 362: 841-844. 10.1038/362841a0.CrossRefPubMed Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature. 1993, 362: 841-844. 10.1038/362841a0.CrossRefPubMed
9.
go back to reference Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E: Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest. 1999, 103: 159-165. 10.1172/JCI5028.CrossRefPubMedPubMedCentral Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E: Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest. 1999, 103: 159-165. 10.1172/JCI5028.CrossRefPubMedPubMedCentral
10.
go back to reference Borgström P, Hillan KJ, Sriramarao P, Ferrara N: Complete inhibition of angiogenesis and growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res. 1996, 56: 4032-4039.PubMed Borgström P, Hillan KJ, Sriramarao P, Ferrara N: Complete inhibition of angiogenesis and growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res. 1996, 56: 4032-4039.PubMed
12.
13.
go back to reference Wang GL, Jiang BH, Rue EA, Semenza GL: Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA. 1995, 92: 5510-5514. 10.1073/pnas.92.12.5510.CrossRefPubMedPubMedCentral Wang GL, Jiang BH, Rue EA, Semenza GL: Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA. 1995, 92: 5510-5514. 10.1073/pnas.92.12.5510.CrossRefPubMedPubMedCentral
14.
go back to reference Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL: Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996, 16: 4604-4613.CrossRefPubMedPubMedCentral Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL: Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996, 16: 4604-4613.CrossRefPubMedPubMedCentral
15.
go back to reference Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxwell P, Koch CJ, Ratcliffe P, Moons L, Jain RK, Collen D, Keshert E: Role of HIF-1 in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature. 1998, 394: 485-490. 10.1038/28867.CrossRefPubMed Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxwell P, Koch CJ, Ratcliffe P, Moons L, Jain RK, Collen D, Keshert E: Role of HIF-1 in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature. 1998, 394: 485-490. 10.1038/28867.CrossRefPubMed
16.
go back to reference Brugarolas J, Kaelin WG: Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes. Cancer Cell. 2004, 6: 7-10. 10.1016/j.ccr.2004.06.020.CrossRefPubMed Brugarolas J, Kaelin WG: Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes. Cancer Cell. 2004, 6: 7-10. 10.1016/j.ccr.2004.06.020.CrossRefPubMed
17.
go back to reference Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 2000, 60: 1306-1311.PubMed Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 2000, 60: 1306-1311.PubMed
18.
go back to reference Kaidi A, Qualtrough D, Williams AC, Paraskeva C: Direct transcriptional upregulation of cyclooxygenase-2 by hypoxia-inducible factor (HIF)-1 promotes colorectal tumor cell survival and enhances HIF-1 transcriptional activity during hypoxia. Cancer Res. 2006, 66: 6683-6691. 10.1158/0008-5472.CAN-06-0425.CrossRefPubMed Kaidi A, Qualtrough D, Williams AC, Paraskeva C: Direct transcriptional upregulation of cyclooxygenase-2 by hypoxia-inducible factor (HIF)-1 promotes colorectal tumor cell survival and enhances HIF-1 transcriptional activity during hypoxia. Cancer Res. 2006, 66: 6683-6691. 10.1158/0008-5472.CAN-06-0425.CrossRefPubMed
19.
go back to reference Liu XH, Kirschenbaum A, Yao S, Stearns ME, Holland JF, Claffey K, Levine AC: Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line. Clin Exp Metast. 1999, 17: 687-694. 10.1023/A:1006728119549.CrossRef Liu XH, Kirschenbaum A, Yao S, Stearns ME, Holland JF, Claffey K, Levine AC: Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line. Clin Exp Metast. 1999, 17: 687-694. 10.1023/A:1006728119549.CrossRef
20.
go back to reference Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998, 93: 705-716. 10.1016/S0092-8674(00)81433-6.CrossRefPubMed Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998, 93: 705-716. 10.1016/S0092-8674(00)81433-6.CrossRefPubMed
21.
go back to reference Philp AJ, Campbell IG, Leet C, Vincan E, Rockman SP, Whitehead RH, Thomas RJ, Phillips WA: The phosphatidylinositol 3’-kinase p85α gene is an oncogene in human ovarian and colon tumors. Cancer Res. 2001, 61: 7426-7429.PubMed Philp AJ, Campbell IG, Leet C, Vincan E, Rockman SP, Whitehead RH, Thomas RJ, Phillips WA: The phosphatidylinositol 3’-kinase p85α gene is an oncogene in human ovarian and colon tumors. Cancer Res. 2001, 61: 7426-7429.PubMed
22.
go back to reference Jiang BH, Jiang GQ, Zheng JZ, Lu ZM, Hunter T, Vogt PK: Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor. Cell Growth Differ. 2001, 12: 363-369.PubMed Jiang BH, Jiang GQ, Zheng JZ, Lu ZM, Hunter T, Vogt PK: Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor. Cell Growth Differ. 2001, 12: 363-369.PubMed
23.
go back to reference Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, Semenza GL: Modulation of hypoxiainducible factor 1 alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 2000, 60: 1541-1545.PubMed Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, Semenza GL: Modulation of hypoxiainducible factor 1 alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 2000, 60: 1541-1545.PubMed
24.
go back to reference Kopelovich L, Fay JR, Sigman CC, Crowell JA: The mammalian target of rapamycin pathway as a potential target for cancer chemoprevention. Cancer Epidemiol Biomarkers Prev. 2007, 16: 1330-1340. 10.1158/1055-9965.EPI-07-0045.CrossRefPubMed Kopelovich L, Fay JR, Sigman CC, Crowell JA: The mammalian target of rapamycin pathway as a potential target for cancer chemoprevention. Cancer Epidemiol Biomarkers Prev. 2007, 16: 1330-1340. 10.1158/1055-9965.EPI-07-0045.CrossRefPubMed
25.
go back to reference Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, Giaccia AJ, Abraham RT: Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin. Mol Cell Biol. 2002, 22: 7004-7014. 10.1128/MCB.22.20.7004-7014.2002.CrossRefPubMedPubMedCentral Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, Giaccia AJ, Abraham RT: Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin. Mol Cell Biol. 2002, 22: 7004-7014. 10.1128/MCB.22.20.7004-7014.2002.CrossRefPubMedPubMedCentral
26.
go back to reference Zhang YJ, Bao YJ, Dai Q, Yang WY, Cheng P, Zhu LM, Wang BJ, Jiang FH: mTOR signaling is involved in indomethacin and nimesulide suppression of colorectal cancer cell growth via a COX-2 independent pathway. Ann Surg Oncol. 2011, 18 (2): 580-588. 10.1245/s10434-010-1268-9.CrossRefPubMed Zhang YJ, Bao YJ, Dai Q, Yang WY, Cheng P, Zhu LM, Wang BJ, Jiang FH: mTOR signaling is involved in indomethacin and nimesulide suppression of colorectal cancer cell growth via a COX-2 independent pathway. Ann Surg Oncol. 2011, 18 (2): 580-588. 10.1245/s10434-010-1268-9.CrossRefPubMed
27.
go back to reference Lipskar AM, Glick RD, Huang J, Fisher JC, DeVoti J, Pica R, Edelman M, Steinberg BM, Soffer SZ: Cyclooxygenase 2 mediates the antiangiogenic effect of rapamycin in Ewing sarcoma. J Pediatr Surg. 2009, 44 (6): 1139-1146. 10.1016/j.jpedsurg.2009.02.037.CrossRefPubMed Lipskar AM, Glick RD, Huang J, Fisher JC, DeVoti J, Pica R, Edelman M, Steinberg BM, Soffer SZ: Cyclooxygenase 2 mediates the antiangiogenic effect of rapamycin in Ewing sarcoma. J Pediatr Surg. 2009, 44 (6): 1139-1146. 10.1016/j.jpedsurg.2009.02.037.CrossRefPubMed
28.
go back to reference Kazemi S, Wenzel D, Kolossov E, Lenka N, Raible A, Sasse P, Hescheler J, Addicks K, Fleischmann BK, Bloch W: Differential role of bFGF and VEGF for vasculogenesis. Cell Physiol Biochem. 2002, 12: 55-62. 10.1159/000063781.CrossRefPubMed Kazemi S, Wenzel D, Kolossov E, Lenka N, Raible A, Sasse P, Hescheler J, Addicks K, Fleischmann BK, Bloch W: Differential role of bFGF and VEGF for vasculogenesis. Cell Physiol Biochem. 2002, 12: 55-62. 10.1159/000063781.CrossRefPubMed
29.
go back to reference Segrelles C, Ruiz S, Santos M, Martínez-Palacio J, Lara MF, Paramio JM: Akt mediates an angiogenic switch in transformed keratinocytes. Carcinogenesis. 2004, 25: 1137-1147. 10.1093/carcin/bgh132.CrossRefPubMed Segrelles C, Ruiz S, Santos M, Martínez-Palacio J, Lara MF, Paramio JM: Akt mediates an angiogenic switch in transformed keratinocytes. Carcinogenesis. 2004, 25: 1137-1147. 10.1093/carcin/bgh132.CrossRefPubMed
30.
go back to reference Chen PN, Hsieh YS, Chiou HL, Chu SC: Silibinin inhibits cell invasion through inactivation of both PI3K-AKT and MAPK signaling pathways. Chem Biol Interact. 2005, 156: 141-150. 10.1016/j.cbi.2005.08.005.CrossRefPubMed Chen PN, Hsieh YS, Chiou HL, Chu SC: Silibinin inhibits cell invasion through inactivation of both PI3K-AKT and MAPK signaling pathways. Chem Biol Interact. 2005, 156: 141-150. 10.1016/j.cbi.2005.08.005.CrossRefPubMed
31.
go back to reference Bhat TA, Singh RP: Tumor angiogenesis - A potential target in cancer chemoprevention. Food Chem Toxicol. 2008, 46: 1334-1345. 10.1016/j.fct.2007.08.032.CrossRefPubMed Bhat TA, Singh RP: Tumor angiogenesis - A potential target in cancer chemoprevention. Food Chem Toxicol. 2008, 46: 1334-1345. 10.1016/j.fct.2007.08.032.CrossRefPubMed
32.
go back to reference Yuan Y, Hilliard G, Ferguson T, Millhorn DE: Cobalt inhibits the interaction between hypoxia-inducible factor-alpha and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor-alpha. J Biol Chem. 2003, 278 (18): 15911-15916. 10.1074/jbc.M300463200.CrossRefPubMed Yuan Y, Hilliard G, Ferguson T, Millhorn DE: Cobalt inhibits the interaction between hypoxia-inducible factor-alpha and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor-alpha. J Biol Chem. 2003, 278 (18): 15911-15916. 10.1074/jbc.M300463200.CrossRefPubMed
33.
go back to reference Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL: Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem. 2002, 277: 38205-38211. 10.1074/jbc.M203781200.CrossRefPubMed Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL: Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem. 2002, 277: 38205-38211. 10.1074/jbc.M203781200.CrossRefPubMed
34.
go back to reference Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF, Taketo MM: Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell. 1996, 87: 803-809. 10.1016/S0092-8674(00)81988-1.CrossRefPubMed Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF, Taketo MM: Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell. 1996, 87: 803-809. 10.1016/S0092-8674(00)81988-1.CrossRefPubMed
35.
go back to reference Jung HJ, Shim JS, Suh YG, Kim YM, Ono M, Kwon HJ: Potent inhibition of in vivo angiogenesis and tumor growth by a novel cyclooxygenase-2 inhibitor, enoic acanthoic acid. Cancer Sci. 2007, 98: 1943-1948. 10.1111/j.1349-7006.2007.00617.x.CrossRefPubMed Jung HJ, Shim JS, Suh YG, Kim YM, Ono M, Kwon HJ: Potent inhibition of in vivo angiogenesis and tumor growth by a novel cyclooxygenase-2 inhibitor, enoic acanthoic acid. Cancer Sci. 2007, 98: 1943-1948. 10.1111/j.1349-7006.2007.00617.x.CrossRefPubMed
36.
go back to reference Zhong H, Willard M, Simons J: NS398 reduces hypoxia-inducible factor (HIF)-1alpha and HIF-1 activity: multiple-level effects involving cyclooxygenase-2 dependent and independent mechanisms. Int J Cancer. 2004, 112: 585-595. 10.1002/ijc.20438.CrossRefPubMed Zhong H, Willard M, Simons J: NS398 reduces hypoxia-inducible factor (HIF)-1alpha and HIF-1 activity: multiple-level effects involving cyclooxygenase-2 dependent and independent mechanisms. Int J Cancer. 2004, 112: 585-595. 10.1002/ijc.20438.CrossRefPubMed
37.
go back to reference Höckel M, Vaupel P: Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 2001, 93: 266-276. 10.1093/jnci/93.4.266.CrossRefPubMed Höckel M, Vaupel P: Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 2001, 93: 266-276. 10.1093/jnci/93.4.266.CrossRefPubMed
38.
go back to reference Raychowdhury R, Schäfer G, Fleming J, Rosewicz S, Wiedenmann B, Wang TC, Höcker M: Interaction of early growth response protein 1 (Egr-1), specificity protein 1 (Sp1), and cyclic adenosine 3050-monophosphate response element binding protein (CREB) at a proximal response element is critical for gastrin-dependent activation of the chromogranin A promoter. Mol Endocrinol. 2002, 16: 2802-2818. 10.1210/me.2001-0292.CrossRefPubMed Raychowdhury R, Schäfer G, Fleming J, Rosewicz S, Wiedenmann B, Wang TC, Höcker M: Interaction of early growth response protein 1 (Egr-1), specificity protein 1 (Sp1), and cyclic adenosine 3050-monophosphate response element binding protein (CREB) at a proximal response element is critical for gastrin-dependent activation of the chromogranin A promoter. Mol Endocrinol. 2002, 16: 2802-2818. 10.1210/me.2001-0292.CrossRefPubMed
39.
go back to reference Fukuda R, Kelly B, Semenza GL: Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1. Cancer Res. 2003, 63: 2330-2334.PubMed Fukuda R, Kelly B, Semenza GL: Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1. Cancer Res. 2003, 63: 2330-2334.PubMed
40.
go back to reference Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL: HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1α (HIF-1α) synthesis: novel mechanism for HIF-mediated vascular endothelial growth factor expression. Mol Cell Biol. 2001, 21 (12): 3995-4004. 10.1128/MCB.21.12.3995-4004.2001.CrossRefPubMedPubMedCentral Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL: HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1α (HIF-1α) synthesis: novel mechanism for HIF-mediated vascular endothelial growth factor expression. Mol Cell Biol. 2001, 21 (12): 3995-4004. 10.1128/MCB.21.12.3995-4004.2001.CrossRefPubMedPubMedCentral
41.
go back to reference Salceda S, Caro J: Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem. 1997, 272: 22642-22647.PubMed Salceda S, Caro J: Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem. 1997, 272: 22642-22647.PubMed
42.
go back to reference Land SC, Tee AR: Hypoxia-inducible factor 1α is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling Motif. J Biol Chem. 2007, 282: 20534-20543. 10.1074/jbc.M611782200.CrossRefPubMed Land SC, Tee AR: Hypoxia-inducible factor 1α is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling Motif. J Biol Chem. 2007, 282: 20534-20543. 10.1074/jbc.M611782200.CrossRefPubMed
43.
go back to reference Macarthur M, Hold GL, El-Omar EM: Inflammation and Cancer II. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy. Am J Physiol Gastrointest Liver Physiol. 2004, 286: G515-G520. 10.1152/ajpgi.00475.2003.CrossRefPubMed Macarthur M, Hold GL, El-Omar EM: Inflammation and Cancer II. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy. Am J Physiol Gastrointest Liver Physiol. 2004, 286: G515-G520. 10.1152/ajpgi.00475.2003.CrossRefPubMed
44.
go back to reference Pajdo R, Brzozowski T, Konturek PC, Kwiecien S, Konturek SJ, Sliwowski Z, Pawlik M, Ptak A, Drozdowicz D, Hahn EG: Ischemic preconditioning, the most effective gastroprotective intervention: involvement of prostaglandins, nitric oxide, adenosine and sensory nerves. Eur J Pharmacol. 2001, 427: 263-276. 10.1016/S0014-2999(01)01246-8.CrossRefPubMed Pajdo R, Brzozowski T, Konturek PC, Kwiecien S, Konturek SJ, Sliwowski Z, Pawlik M, Ptak A, Drozdowicz D, Hahn EG: Ischemic preconditioning, the most effective gastroprotective intervention: involvement of prostaglandins, nitric oxide, adenosine and sensory nerves. Eur J Pharmacol. 2001, 427: 263-276. 10.1016/S0014-2999(01)01246-8.CrossRefPubMed
45.
go back to reference Stasinopoulos I, O'Brien DR, Bhujwalla ZM: Inflammation, but not hypoxia, mediated HIF-1α activation depends on COX-2. Cancer Biol Ther. 2009, 8: 31-35.CrossRefPubMedPubMedCentral Stasinopoulos I, O'Brien DR, Bhujwalla ZM: Inflammation, but not hypoxia, mediated HIF-1α activation depends on COX-2. Cancer Biol Ther. 2009, 8: 31-35.CrossRefPubMedPubMedCentral
46.
go back to reference Gately S: The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metast Rev. 2000, 19: 19-27. 10.1023/A:1026575610124.CrossRef Gately S: The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metast Rev. 2000, 19: 19-27. 10.1023/A:1026575610124.CrossRef
47.
go back to reference Troiani T, Lockerbie O, Morrow M, Ciardiello F, Eckhardt SG: Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases. Mol Cancer Ther. 2006, 5 (7): 1883-1894. 10.1158/1535-7163.MCT-06-0055.CrossRefPubMed Troiani T, Lockerbie O, Morrow M, Ciardiello F, Eckhardt SG: Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases. Mol Cancer Ther. 2006, 5 (7): 1883-1894. 10.1158/1535-7163.MCT-06-0055.CrossRefPubMed
48.
go back to reference Fan F, Wey JS, McCarty MF, Belcheva A, Liu W, Bauer TW, Somcio RJ, Wu Y, Hooper A, Hicklin DJ, Ellis LM: Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene. 2005, 24 (16): 2647-2653. 10.1038/sj.onc.1208246.CrossRefPubMed Fan F, Wey JS, McCarty MF, Belcheva A, Liu W, Bauer TW, Somcio RJ, Wu Y, Hooper A, Hicklin DJ, Ellis LM: Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene. 2005, 24 (16): 2647-2653. 10.1038/sj.onc.1208246.CrossRefPubMed
49.
go back to reference Roskoski R: Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol. 2007, 62: 179-213. 10.1016/j.critrevonc.2007.01.006.CrossRefPubMed Roskoski R: Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol. 2007, 62: 179-213. 10.1016/j.critrevonc.2007.01.006.CrossRefPubMed
50.
go back to reference Belotti D, Paganoni P, Manenti L, Garfalo A, Marchini S, Taraboletti G, Giavazzi R: Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res. 2003, 63: 5224-5229.PubMed Belotti D, Paganoni P, Manenti L, Garfalo A, Marchini S, Taraboletti G, Giavazzi R: Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res. 2003, 63: 5224-5229.PubMed
51.
go back to reference Bhoopathi P, Chetty C, Kunigal S, Vanamala SK, Rao JS, Lakka SS: Blockade of tumor growth due to MMP-9 inhibition is mediated by sequential activation of β1 integrin, ERK and NF-κB. J Biol Chem. 2008, 283 (3): 1545-1552.CrossRefPubMed Bhoopathi P, Chetty C, Kunigal S, Vanamala SK, Rao JS, Lakka SS: Blockade of tumor growth due to MMP-9 inhibition is mediated by sequential activation of β1 integrin, ERK and NF-κB. J Biol Chem. 2008, 283 (3): 1545-1552.CrossRefPubMed
Metadata
Title
Astragalus saponins downregulate vascular endothelial growth factor under cobalt chloride-stimulated hypoxia in colon cancer cells
Authors
Pui-Ching Law
Kathy K Auyeung
Lok-Yi Chan
Joshua K Ko
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2012
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/1472-6882-12-160

Other articles of this Issue 1/2012

BMC Complementary Medicine and Therapies 1/2012 Go to the issue